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Abstract/Summary 
Objective: To investigate the impact of mandatory iodine fortification (IF) on the incidence of 
nosological subtypes of overt thyrotoxicosis and hypothyroidism. 
Design: We identified and scrutinized all possible new cases of overt thyrotoxicosis and 
hypothyroidism in an open cohort in Northern Jutland (n=309,434 January 1st, 1997) during the years 
2014-16. Individual medical history was evaluated to verify and detail the incidence of overt thyroid 
dysfunction and for classification into nosological subtypes. A number of cases were excluded during 
final verification due to spontaneous normalization of thyroid function, as they had no medical 
history suggesting a known condition, which could transiently affect thyroid function 
(subacute/silent thyroiditis, PPTD and iatrogenic thyroid dysfunction). An identical survey was 
conducted in 1997-2000 prior to mandatory IF of salt (13 µg/g) that was in effect from year 2001. 
Results: The standardized incidence rate (SIR) of verified overt thyrotoxicosis decreased markedly 
from 97.5/100,000/year in 1997-00 to 48.8 in 2014-16 (SIRR: 0.50 (95% CI: 0.45-0.56)). This was due 
to a distinct decrease in the SIR of multinodular toxic goitre (SIRR: 0.18 (0.15-0.23)), solitary toxic 
adenoma (SIRR: 0.26 (0.16-0.43)) and to a lesser degree Graves’ disease (SIRR: 0.67 (0.56-0.79)). SIR 
for overt hypothyroidism was unaltered by 2014-16 (SIRR: 1.03 (0.87-1.22)). However, age 
distribution shifted with more young and fewer elderly cases of verified overt hypothyroidism. 
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Conclusion: Mandatory IF caused a substantial reduction in SIR of verified overt thyrotoxicosis 
(especially of nodular origin) while avoiding an increase in SIR of verified overt hypothyroidism. 
Introduction 
Iodine deficiency (ID) has been recognized as an important health issue globally with efforts to 
combat iodine deficiency disorders (IDD) for more than a century. Still, the latest assessment from 
the World Health Organization (WHO) indicate that IDD affect 31% of the global population1. 
The population of Denmark was shown to suffer from ID during the 1990s mainly related to a low 
iodine content in tap water2. Mild ID was common in the Eastern parts of the country while 
moderate ID was frequent in the Western parts3. Thyrotoxicosis due to autonomously functioning 
thyroid nodules was very frequent among the elderly in the Western parts of Denmark4, as was the 
occurrence of nontoxic thyroid nodules5. Pregnant women experienced a tendency for increased 
TSH during late pregnancy, possibly indicating insufficiency of thyroid hormone production6. Thus, a 
Danish iodine fortification (IF) program was initiated in July 1998 with iodization of salt at a level of 8 
µg/g on a voluntary basis7. However, this proved to be insufficient in achieving a 50 µg increase in 
average daily iodine intake and was replaced by a mandatory iodization (13 µg/g) of all table salt and 
salt used for commercial production of bread in July 2000. Permission was granted for selling 
preexisting storages of uniodized salt after July 2000, thus universal salt iodization was not fully in 
effect before the year 2001. A multifaceted program for monitoring of the effects of salt iodization in 
the population was initiated before any IF was in place8 and is still ongoing.  
Results from the registration of new cases of overt thyrotoxicosis and hypothyroidism have been 
published for the first 20-21 years9–12. This registration was based on a Register Database applying a 
diagnostic algorithm to all thyroid function tests (TFTs) taken within the cohort areas and then 
excluding the cases known to the Register Database or the current general practitioner (GP) of each 
patient.  
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The present study adds a scrutinized review of all health records for each individual case in order to 
clarify the distinct nosological subtype of thyroid dysfunction (thyrotoxicosis or hypothyroidism). We 
compared the pre-mandatory iodization period (1997-00) to a post-iodization period (2014-16). 
 
Methods and Materials 
Population cohort 
The present study cohort comprised a population of 309,434 subjects (January 1st, 1997) prior to the 
implementation of salt iodization in Denmark. Moderate ID was widespread in the western parts of 
Denmark including our study cohort around Aalborg City, Northern Jutland (median UIC = 45 µg/l in 
1997-98 among subjects not using iodine containing supplements; 53 µg/l if all subjects were 
included)13. After universal salt iodization, the median UIC within the study cohort increased to a 
level of 86 µg/l in 2004-0514 and 74 µg/l15 in 2008-10. The Danish municipalities were rearranged by 
January 2007 as a part of a national structural reform. This rearrangement slightly decreased the size 
of the area encompassing our study cohort. At the start of the present study period (January 1st, 
2014) the study cohort comprised 272,954 subjects, while the total number of person-years covered 
by the present study period (2014-16) amounts to 825,842. The distribution of the nosological 
subtypes of thyroid dysfunction were described in detail for the cohort population during the years 
1997-2000 before the mandatory iodine fortification16,17. Information on the composition of the 
cohort was provided by Statistics Denmark18.  
Identification of potential new cases with thyroid dysfunction 
All potential new cases of biochemically overt thyroid dysfunction were identified, manually verified 
and subsequently classified according to their nosological subtype of thyrotoxicosis or 
hypothyroidism in an open cohort located in Northern Jutland for the years 2014-16. The process of 
identification has been extensively described19. In brief: 
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All TFTs sampled within the cohort area were recorded in a dedicated register database. Potential 
new cases of overt thyrotoxicosis were identified based on a suppressed serum TSH (<0.2mU/l) 
combined with an elevated serum total T4 (>140nmol/l) and/or an elevated serum total T3 
(>2.7nmol/l). Potential new cases of hypothyroidism was identified based on an elevated serum TSH 
(>5.0mU/l) and a low total T4 (<60nmol/l). Cases previously verified in the database as hyper- or 
hypothyroid were excluded. 
A similar identification process for cases of overt thyroid dysfunction had been performed in an open 
cohort in the Danish capital Copenhagen with previous mild ID from 1997-20089–12. Unfortunately 
this registration had to be concluded in 2008 due to staff limitations. 
Data collection on the potential new cases of thyroid dysfunction 
A total of 666 patients were identified by the register database and confirmed by their GPs as 
potential new cases of overt thyrotoxicosis, while 403 patients were identified as potential new 
cases of overt hypothyroidism during the years 2014-16. In comparison, 1601 and 410 potential new 
cases of thyrotoxicosis and hypothyroidism were identified during the years 1997-00. All cases were 
individually scrutinized by examining their hospital records, medicinal databases (used by private 
practitioners and hospital departments), subsequent TFTs, TSH receptor antibodies (TRAb) 
measurements and thyroid scintigraphies performed by the department of nuclear medicine.  
Verification process of incident cases 
All patients underwent a diagnostic algorithm in order to verify or reject incident overt thyroid 
dysfunction, as illustrated in figure 1. Patients with potential new overt biochemical thyroid 
dysfunction, who were not previously recorded as thyrotoxic or hypothyroid patients by our Register 
Database or by the patients’ GP, were verified if either of the following were true:  
1) Sustained overt biochemical thyroid dysfunction, i.e. a confirmatory TFT at least 3 weeks later.  
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2) Normalization of thyroid function due to treatment for thyrotoxicosis (anti-thyroid medication, 
radioiodine therapy or thyroid surgery) or hypothyroidism (levo-thyroxine (L-T4) therapy). 
3) Normalization of thyroid function without treatment but with a history suggesting a transient 
condition of thyroid dysfunction, such as: subacute thyroiditis (SAT), silent thyroiditis, postpartum 
thyroid dysfunction (PPTD), radiation-induced thyroid dysfunction, surgical manipulation of the 
thyroid gland, radioiodine-induced thyroid dysfunction, medication-induced thyroid dysfunction 
(amiodarone, lithium, interferons, interleukins and monoclonal antibodies). 
Through use of the algorithm described above and a list of specific exclusion criteria (see appendix), 
we were able to verify 659 patients with overt thyroid dysfunction out of 1069 (thyrotoxicosis: 408, 
hypothyroidism: 251).    
Classification of incident cases into nosological subtypes of thyrotoxicosis and hypothyroidism 
Each of the verified cases of thyroid dysfunction were classified into one of the following categories 
based on their medical history, thyrotropine receptor antibody (TRAb) measurements and thyroid 
scintigraphy: 
a) Graves’ disease (GD) with thyrotoxicosis: positive TRAb measurement (TRAb+, TRAb > 1.0 IU/l) 
and/or a nonsuppressed homogeneous TcO4
- uptake within the entire thyroid gland on scintigraphy 
(n=181). 
b) Multinodular toxic goitre (MNTG): a heterogeneous uptake on thyroid scintigraphy with at least 
two nodules of enhanced TcO4
- accumulation combined with absent or diminished uptake in the rest 
of the gland. If TRAb was negative or not measured, the diagnosis was MNTG (n=74). 
c) ‘Mixed type’ thyrotoxicosis (Marine-Lenhart syndrome): patients with a positive TRAb 
measurement but a MNTG like pattern on thyroid scintigraphy (n=71). 
d) Solitary toxic adenoma (STA): a single nodule with enhanced TcO4
- uptake combined with absent 
or low TcO4
- accumulation in rest of the thyroid gland (n=13). 
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e) SAT (subacute thyroiditis/de Quervain thyroiditis): transient thyrotoxicosis and/or 
hypothyroidism, with no medical history which could otherwise explain the transient period of 
thyroid dysfunction (amiodarone, lithium, interferon, interleukin, monoclonal antibodies, 
radioiodine treatment, radiation or surgery) and with at least two of three SAT criteria fulfilled: 
anterior neck pain; absent or low TcO4
- uptake with no visible thyroid nodules on scintigraphy; or 
elevated erythrocyte sedimentation rate / C-reactive protein (thyrotoxicosis: n=24, hypothyroidism: 
n=1). 
f) Silent thyroiditis: transient thyrotoxicosis with absent or low TcO4
- uptake and no presence of 
anterior neck pain or elevated erythrocyte sedimentation rate / C-reactive protein. Similar to SAT, no 
other explanation for the transient period of thyroid dysfunction should be detectable in the 
patient’s medical history (n=6). 
g) Postpartum thyroid dysfunction (PPTD): overt thyroid dysfunction presenting within one year 
after delivery. If TRAb was negative or not measured in the case of thyrotoxicosis, PPTD was the 
diagnosis. If TRAb was positive, the patient was classified as GD (thyrotoxicosis: n=15, 
hypothyroidism: n=23). 
h) Amiodarone-associated thyroid dysfunction: overt thyrotoxicosis or hypothyroidism diagnosed 
during or within 12 months after amiodarone treatment (thyrotoxicosis: n=6, hypothyroidism: n=11). 
i) Radioiodine-associated thyroid dysfunction: transient overt thyrotoxicosis developed within a 
month after radioiodine treatment of non-toxic goitre was performed, or overt hypothyroidism 
developed within one year (thyrotoxicosis: n=4, hypothyroidism: n=5). 
j) Lithium-associated thyroid dysfunction: overt thyroid dysfunction in patients previously (<12 
months) or currently treated with lithium (thyrotoxicosis: n=5, hypothyroidism: n=4). 
k) ‘Manipulation thyroiditis’ with thyrotoxicosis: transient thyrotoxicosis developed shortly after 
thyroid manipulation during surgery on thyroid or parathyroid gland (n=3). 
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l) Thyroid dysfunction associated with previous (<12months) or current treatment with interferon 
(IFN), interleukin (IL) or monoclonal antibodies (thyrotoxicosis: n=4, hypothyroidism: n=5). 
m) Radiation-associated thyroid dysfunction: overt thyrotoxicosis within 3 months after any 
radiation therapy against the neck region or overt hypothyroidism within one year (thyrotoxicosis: 
n=2, hypothyroidism: n=7). 
n) Surgically induced hypothyroidism: overt hypothyroidism within one year after hemithyrodectomi 
or total thyrodectomi (n=12). Patients who underwent sufficient L-T4 substitution immediately after 
surgery would logically not emerge as hypothyroid. 
o) Congenital hypothyroidism: identified through the Danish neonatal screening program (n=3). 
p) Spontaneous hypothyroidism: overt hypothyroidism in patients without any of the above 
described conditions (n=180). We have previously shown that this combined group of patients with 
hypothyroidism due to Hashimoto’s or Ort’s disease almost exclusively (>99%) harbored TPO-Ab 
and/or Tg-Ab20. 
Of the 408 verified cases of thyrotoxicosis, we were able to classify 380 using the criteria described 
above. However, a small number of patients (n=28) had no TRAb measurement or thyroid 
scintigraphy performed. From their medical history, we knew they did not suffer from the entities e-
m. In accordance with our previous study, we used nearest neighbor hot deck-imputation21 to 
classify this small group of patients (6.9%) into the subgroups a-d (GD/MNTG/mixed-type/STA: 
n=10/9/8/1).  Nearest neighbor hot deck-imputation did not alter any of the results of the present 
study. 
 
 
 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Statistical methods 
The standardized incidence rate (SIR) of each nosological subtype was calculated according to the 
principle of direct standardization22. The Danish population as of January 1st, 1999 was used as the 
standard population to allow for comparison with data from the same cohort during the years 
before initiation of effective IF (1997-2000). The 95% confidence intervals of the standardized 
incidence rate ratios (SIRR) were used to determine any significant differences.   
The study was approved by the National Committee on Health Research Ethics in Denmark and by 
The Danish Data Protection Agency.  
 
Results 
Incidence of verified thyrotoxicosis and its subtypes 
The overall SIR of verified thyrotoxicosis decreased markedly from 97.5 during the pre-iodine 
fortification years 1997-00 to 48.8/100,000/year in 2014-16, with a SIRR of 0.50 (95% CI: 0.45-0.56), 
(figure 2). The SIR of MNTG decreased from 44.5 to 8.2 (SIRR: 0.18 (0.15-0.23)), GD from 33.2 to 22.2 
(SIRR: 0.67 (0.56-0.79)) and STA from 6.1 to 1.6 (SIRR: 0.26 (0.16-0.43)). No changes were observed 
in mixed-type thyrotoxicosis (SIRR: 1.14 (0.83-1.58)), post partum thyrotoxicosis (SIRR: 1.03 (0.53-
1.99)) and thyrotoxicosis due to iatrogenic causes (SIRR: 1.09 (0.64-1.86)). Only the SIR of SAT 
increased significantly among the subtypes of thyrotoxicosis during the study period from 1.8 to 3.7 
(SIRR: 2.07 (1.15-3.72)). The SIR of thyrotoxicosis among both men and women decreased 
significantly from 1997-00 to 2014-16; SIR for men from 33.0 to 21.3 (SIRR: 0.65 (0.51-0.82)) and SIR 
for women from 160.4 to 75.6 (SIRR: 0.47 (0.42-0.53)). 
When divided into three age groups (young, middle-aged and elderly: 20-39, 40-59 and 60+ years) a 
decrease in SIR of thyrotoxicosis was evident in all three groups, though only statistically significant 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
among the middle-aged (40-59 y) and elderly (60+ y). Young: (SIRR: 0.80 (0.63-1.02)), middle-aged 
(SIRR: 0.67 (0.56-0.80)) and elderly (SIRR: 0.30 (0.25-0.35)), (figure 3).  
Incidence of verified hypothyroidism and its subtypes 
No significant change in the overall SIR of verified hypothyroidism was evident from the years 1997-
00 (29.4/100.000/year) to 2014-16 (30.3; SIRR: 1.03 (0.87-1.22)), (figure 4). The SIR of spontaneous 
presumably autoimmune hypothyroidism decreased non-significantly from 23.3 to 21.6 (SIRR: 0.93 
(0.77-1.12)). The SIR of post partum hypothyroidism increased from 1.8 to 3.3 (SIRR: 1.83 (0.97-
3.44)), hypothyroidism due to iatrogenic causes from 3.1 to 4.8 (SIRR: 1.58 (1.00-2.50)), while 
hypothyroidism due to other causes (SAT, congenital, sarcoidosis etc.) experienced a non-significant 
decline from 1.3 to 0.6 (SIRR: 0.44 (0.17-1.16)). The SIR of hypothyroidism did not change 
significantly among either men or women in the present study; SIR for men from 12.6 to 16.9 (SIRR: 
1.34 (0.96-1.86)) and among women from 45.8 to 43.4 (SIRR: 0.95 (0.78-1.15)). 
The SIR of hypothyroidism behaved differently across the three aforementioned age groups. A 
significant increase in SIR was evident among the young (20-39 y) from 14.7 to 26.5 (SIRR: 1.81 (1.20-
2.72)), while a non-significant increase was present among the middle-aged from 33.0 to 43.8 (SIRR: 
1.33 (1.00-1.77)), (figure 3). However, significant decrease in SIR was evident among the elderly (60+ 
y) from 76.5 to 48.1 (SIRR: 0.63 (0.49-0.80)), thus preventing an increase in the overall SIR of 
hypothyroidism for the whole population.        
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Discussion 
Principal findings 
In Denmark, the overall SIR of overt thyrotoxicosis decreased 50% after 14-16 years of mandatory IF, 
while the overall SIR of overt hypothyroidism remained constant. This remarkable reduction in 
thyrotoxicosis incidence was primarily due to lower incidence of MNTG, STA and secondarily a 
smaller reduction in the GD incidence.  
Comparison with other studies 
Our finding of a lower incidence of thyrotoxicosis many years after IF is in accordance with several 
other studies23–25. After increasing the salt iodization in Switzerland from 7.5 to 15 ppm in 1980, 
decreases in incidence rates of MNTG and GD were observed with strong similarities to those 
observed in the present study23. The overall incidence rate of thyrotoxicosis was reduced by 56% in 
1988-89 compared to 50 % in the present study. The incidences of MNTG and GD were reduced by 
73% and 33% respectively compared to 82% and 33% in the present study. The study from 
Switzerland however, differs from the current study in its design, as only patients referred to one 
specific hospital were included. Furthermore, it differs in the preexisting ID level of the study 
population (changed from mild ID to recommended iodine intake in Switzerland while our cohort 
population changed from moderate to mild ID).  
Similarly to Switzerland the salt iodization in Austria was doubled from 7.5 to 15 ppm in 1990. 
Recording the incidence rate of thyrotoxicosis from 14 departments of nuclear medicine from 1987-
1995 revealed an initial peak and a subsequent decline in incidence rates of both GD and thyroid 
autonomy24. This study had only five years of follow-up after the increase in salt iodization, which 
may explain why the incidence at the end of the study did not reach below baseline level.  
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In Slovenia salt iodization was increased from 10 to 25 ppm of potassium iodide in 1999. The 
incidence rate of GD, thyroid autonomy and Hashimoto’s thyroiditis were determined by referrals to 
the Thyroid Department at the University Medical Centre Ljubljana25. From 1999 to 2009 the 
incidence rate of thyrotoxicosis due to thyroid autonomy (MNTG and STA) decreased by 27%, while 
no difference to baseline level was observed for GD. The incidence rate of Hashimoto’s thyroiditis 
increased markedly during the study period to a level 127% above baseline in 2009. This discrepancy 
with the findings of the current study likely results from the fact that both overt and subclinical 
hypothyroidism were compiled in the Slovenian study. 
The Pescopagano-study in Italy examined the prevalence of nodular thyrotoxicosis (MNTG and STA), 
GD and hypothyroidism in an iodine deficient rural community in Northern Italy in 1995 and again in 
2010 after voluntary iodization of salt at a national level was instituted at a level of 30 ppm in 
200526. Neither the prevalence of nodular thyrotoxicosis nor GD changed significantly. The 
prevalence of Hashimoto’s thyroiditis increased significantly from 2.8% in 1995 to 5.0% in 2010. The 
diagnosis was based on compound criteria of thyroid antibodies (Abs), hypoechoic pattern on 
ultrasound and TFTs suggesting thyroid failure. Thus, many of the included patients were euthyroid 
or subclinically hypothyroid. 
As a part of the DanThyr studies, two cross-sectional studies and a follow-up study of the initial 
cross-sectional study were performed before and after introduction of IF in Denmark (1st: 1997-98, 
2nd: 2004-05 and follow-up to the first study: 2008-10). Ultrasonographic examination of the 
participants in the baseline cross-sectional study in 1997-98 and at follow-up in 2008-10 showed a 
lower frequency of both multiple and solitary thyroid nodules during follow-up when participants of 
similar age at the time of examination were compared. Thus, the diminished development of thyroid 
nodules among participants of the same age group after introduction of IF and the disappearance of 
existing nodules may explain the decreased development of MNTG and STA in the present study. 
This would be in accordance with the current conception of how autonomous thyroid nodules 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
develop under conditions of iodine deficiency27. It has been suggested that iodine deficiency may 
cause nodular transformation of the thyroid gland through the following sequence of events: TSH 
induced hyperplasia and increased functional activity may cause increased mutagenesis through 
H2O2 and reactive oxygen species (ROS) formation, and thus allow for gain of function mutations in 
genes involved with thyrocyte growth leading to emergence of autonomous thyrocyte clones27.      
Data from national registers in Denmark confirm many of the findings of the present study. A 23% 
decrease in the use of anti-thyroid medication below pre-fortification level on a national scale was 
observed between 1997 and 201428. Unsurprisingly, radioiodine treatment was much more frequent 
in Denmark before and during the time of IF initiation than during the present study period 
(47.7/100,000/year in 1997 vs 33.1 in 2015)28. The substantial reduction in MNTG and STA 
development seems the likely explanation for this decrease in frequency of radioiodine treatment.             
A significant increase in the prevalence of thyroid peroxidase antibodies (TPO-Abs) and thyroglobulin 
antibodies (Tg-Abs) was evident in the Danish cross-sectional studies from 1997-98 to 2004-05 (TPO-
Ab: 14.3 vs 23.8%; Tg-Ab: 13.7 vs 19.9%; P<0.001)29. From the latest study we have a clear indication 
of the association between the level of TPO-Ab and TSH above the reference range29,30. The increase 
in prevalence of TPO-Ab positivity was most pronounced in the younger age groups and least among 
the elderly29, which corresponds well with the findings of the present study where an increased 
incidence rate of hypothyroidism was observed only among the young.  This may also explain the 
borderline increase in post partum hypothyroidism observed in the present study. 
In the DanThyr cross-sectional studies, the frequency of thyroid autoantibodies was negatively 
associated with smoking, which might explain some of the increased TPO-Ab positivity discovered 
after initiation of IF, as smoking has become significantly less frequent during the last two decades in 
Denmark31.  
Similarly, smoking might be an important factor in explaining the decreased incidence of GD 
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observed in the present study as smoking is positively associated with the onset and severity of 
GD32. 
The number of new patients with TFT results compatible with overt hypothyroidism (TSH>5.0 and 
total T4<60) increased 50% between 1997-98 and 2014-16 in the cohort area utilized in the present 
study12. However, when patients with spontaneous normalization of thyroid function (not requiring 
treatment) and no signs or history of a condition known to cause transitory thyroid dysfunction (e.g. 
SAT, PPTD and iatrogenic causes) were excluded from the analysis, this increase in incidence rate of 
overt hypothyroidism disappeared entirely. Thus, the cause of the previously observed increased 
incidence rate was mild, transitory cases with no need for treatment. 
Strengths and limitations  
The present study utilizes a well-established surveillance program and includes a period with no 
mandatory iodization of salt (4 years), followed by the currently longest follow-up study period of 
mandatory IF (14 years). The study also deals with 13 different nosological entities of overt 
thyrotoxicosis and 10 nosological entities of hypothyroidism. Furthermore, the present study 
includes all possible new cases of overt thyroid dysfunction identified by general practitioners, 
hospital departments and specialists with private practice, thus avoiding the referral bias often seen 
among studies exclusively utilizing data from the secondary healthcare sector23–25. We used identical 
algorithms and criteria (1997-00 vs. 2014-16) for identification, verification and subtype 
classification.   
From 1997-2014 the incident use of thyroid hormone therapy almost doubled on a national scale28. 
This could seem contrary to our results though an increase in treatment of subclinical 
hypothyroidism seems the more likely explanation. Evidence exists to suggest a lower s-TSH 
threshold for initiating L-T4 treatment among hypothyroid patients in Copenhagen between 2001 
and 201533. The median s-TSH upon initiation of L-T4 treatment was 10 mU/l in 2001 and 6.8 in 
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201533. Treating subclinical cases of hypothyroidism could ensure that patients never become 
overtly hypothyroid, thus remaining undetected by our surveillance program.  
It seems highly probable that the diagnostic activity for thyroid dysfunction have increased since the 
initiation of IF in Denmark. This could however, lead to an underestimation of the substantial 
reduction in SIR of overt verified thyrotoxicosis and the absent increase in SIR of overt verified 
hypothyroidism. In Copenhagen the annual number of s-TSH measurement increased 164% from 
2001 to 201533.      
Perspectives and clinical implications 
A small increase in daily iodine intake (<50 µg) among a population with moderate iodine deficiency 
did not increase the incidence rate of sustained verified overt hypothyroidism, but markedly 
decreased the incidence rate of overt thyrotoxicosis with 50 %. Thus, a cautious iodization of salt will 
manage to substantially reduce the burden of overt thyrotoxicosis among an iodine deficient 
population without increasing the incidence of overt hypothyroidism (when mild temporary cases 
with spontaneous normalization of TFTs are excluded). The incidence rates of MNTG and STA in 
particular should be expected to substantially diminish after introduction of IF while the effect on GD 
occurrence remains less obvious. Furthermore, an altered age distribution among both overt 
thyrotoxicosis and hypothyroidism should be expected, with more cases among the young relatively 
to the elderly. 
Conclusion 
Cautious iodine fortification causes a substantial reduction in the incidence rate of overt 
thyrotoxicosis (MNTG and STA especially), without increasing the overall incidence of sustained 
overt hypothyroidism. Development of overt thyroid dysfunction after introduction of IF differs 
significantly among age groups.   
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Legends 
Figure 1: 
Flowchart showing the process of verification for cases of overt thyroid dysfunction. Cases identified 
by the diagnostic algorithms within the cohort area who have not been registered with overt thyroid 
dysfunction prior by either the patients current general practitioner or by the Register Database 
constitute the pool of cases for further evaluation. Cases were first evaluated with respect to 
normalization of thyroid function tests, and then according to whether normalization was the result 
of treatment or a case of spontaneous normalization. Cases of spontaneous normalization were 
verified as true hypothyroid or thyrotoxic patients if their medical history suggested a known 
condition of transient thyroid dysfunction (e.g. subacute thyroiditis, post partum thyroid dysfunction 
or one of several iatrogenic causes). All verified cases were further scrutinized to determine their 
nosological subtype.  
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Figure 2: 
Standardized incidence rates of overt thyrotoxicosis and nosological subtypes per 100,000 per year 
between 1997-00 (pre-iodine fortification period) and 2014-16 (after iodization of salt). Grey 
columns represent data from 1997-00 and white columns data from 2014-16. Stars indicate 
significant change from baseline value (1997-00). 
 
Figure 3: 
Relative change in standardized incidence rate of overt thyrotoxicosis and hypothyroidism between 
1997-00 and 2014-16 among three age groups (20-39, 40-59 and 60+ years). Black arrows represent 
overt thyrotoxicosis and grey arrows represent overt hypothyroidism. Stars indicate significant 
change from baseline value (1997-00). 
 
Figure 4: 
Standardized incidence rates of overt hypothyroidism and nosological subtypes per 100,000 per year 
between 1997-00 (pre-iodine fortification period) and 2014-16 (after iodization of salt). Grey 
columns represent data from 1997-00 and white columns data from 2014-16. 
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Appendix 
Exclusion criteria for potential new cases of overt thyroid dysfunction 
Patients were excluded from the group of verified cases of overt thyroid dysfunction if any of the 
following were present: 
i) Spontaneous normalization without treatment with no signs or history suggesting at transitory 
thyrotoxic or hypothyroid condition (n=201). ii) Patients had previously suffered from overt thyroid 
dysfunction (n=9). iii) Patients were receiving levothyroxine or anti-thyroid medication at the time of 
diagnosis (n=115).  
iv) Presence of gestational transient thyrotoxicosis (n=22). v) An elevated TBG present due to either 
pregnancy or estrogen therapy (n=11). vi) No confirmative blood test result in a patient who 
survived beyond 2 months (n=6). vii) Amiodarone treatment where the thyrotoxic patients did not 
have an elevated total T3 (n=19) (elevated total T4 should be expected in a patient with subclinical 
thyrotoxicosis receiving amiodarone). viii) Treatment was initiated after the patient had shifted from 
overt to subclinical thyroid dysfunction (n=14). ix) Other reasons (n=13), these included cases with 
pituitary disease, children having different reference intervals of total T4 and erroneously being 
included as cases of overt thyrotoxicosis, cases where overt thyroid dysfunction occurred several 
years after spontaneous normalization, one case where the thyroid gland was surgically removed 
before any confirmatory TFT could be performed.   
Thus, the total number of patients excluded was 410 out of 1069. Patients who had no confirmatory 
blood test preformed and died within 2 months were considered true cases whether or not a trigger 
of transient thyroid dysfunction was present or treatment was initiated. 
Patients with possible new overt thyroid dysfunction invited for examination in our center 
A selected number of patients were furthermore contacted by our research group shortly after their 
diagnostic blood sample and invited for a thorough investigation at our research center including: 
several comprehensive questionnaires about their medical history, blood tests for TRAb, anti-TPO 
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Ab, anti-Tg Ab, TBG and thyroglobulin, ultrasonographic examination of the thyroid gland and 
thyroid scintigraphy. Of the 1069 potential new cases in 2014-16, we examined 511 patients at our 
research center (48%). Similarly, 38% of all new cases of overt thyroid dysfunction were examined in 
1997-00. Consent has been obtained from each patient or subject after full explanation of the 
purpose and nature of all procedures used. 
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